Imperial College London

ProfessorEricAboagye

Faculty of MedicineDepartment of Surgery & Cancer

Professor
 
 
 
//

Contact

 

+44 (0)20 3313 3759eric.aboagye

 
 
//

Assistant

 

Mrs Maureen Francis +44 (0)20 7594 2793

 
//

Location

 

GN1Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Publication Type
Year
to

332 results found

Willaime JMY, Turkheimer FE, Kenny LM, Aboagye EOet al., 2013, Quantification of intra-tumour cell proliferation heterogeneity using imaging descriptors of 18F fluorothymidine-positron emission tomography, Physics in medicine and biology, Vol: 58, Pages: 187-203

Intra-tumour heterogeneity is a characteristic shared by all cancers. We explored the use of texture variables derived from images of [(18)F]fluorothymidine-positron emission tomography (FLT-PET), thus notionally assessing the heterogeneity of proliferation in individual tumours. Our aims were to study the range of textural feature values across tissue types, verify the repeatability of these image descriptors and further, to explore associations with clinical response to chemotherapy in breast cancer patients. The repeatability of 28 textural descriptors was assessed in patients who had two FLT-PET scans prior to therapy using relative differences and the intra-class correlation coefficient (ICC). We tested associations between features at baseline and clinical response measured in 11 patients after three cycles of chemotherapy, and explored changes in FLT-PET at one week after the start of therapy. A subset of eight features was characterized by low variations at baseline (<30%) and high repeatability (0.7 ≤ ICC ≤ 1). The intensity distribution profile suggested fewer highly proliferating cells in lesions of non-responders compared to responders at baseline. A true increase in CV and homogeneity was measured in four out of six responders one week after the start of therapy. A number of textural features derived from FLT-PET are altered following chemotherapy in breast cancer, and should be evaluated in larger clinical trials for clinical relevance.

Journal article

Gallo J, Long NJ, Aboagye EO, 2013, Magnetic nanoparticles as contrast agents in the diagnosis and treatment of cancer, CHEMICAL SOCIETY REVIEWS, Vol: 42, Pages: 7816-7833, ISSN: 0306-0012

Journal article

Tietz O, Kamaly N, Smith G, Shamsaei E, Bhakoo KK, Long NJ, Aboagye EOet al., 2013, Design, synthesis and in vitro characterization of fluorescent and paramagnetic CXCR4-targeted imaging agents., Am J Nucl Med Mol Imaging, Vol: 3, Pages: 372-383, ISSN: 2160-8407

The G-protein coupled C-X-C chemokine receptor type 4 (CXCR4) is highly overexpressed in a range of cancers and is therefore an excellent biomarker for cancer imaging. To this end targeted iron oxide nanoparticles were developed and utilised for in vitro imaging of MDA-MB-231 breast cancer cells overexpressing the CXCR4 receptor. Nanoparticles comprising an iron oxide core, encapsulated in a stabilising epichlorohydrin crossed-linked dextran polymer, were conjugated to a cyclopentapeptide with affinity to the CXCR4 receptor. The particles were characterized for their size, surface charge and r2 relaxivity at 4.7 T. MR imaging of the CXCR4 receptor with targeted iron oxide nanoparticles revealed an approximately 3-fold increase in T2 signal enhancement of MDA-MB-231 cells compared to non-targeted controls. Prussian blue staining of labeled MDA-MB-231 cells revealed darker and more intense staining of the cellular membrane. This study demonstrates the potential of targeted iron oxide nanoparticles for the imaging of the CXCR4 receptor by magnetic resonance imaging (MRI).

Journal article

Trousil S, Carroll L, Kalusa A, Aberg O, Kaliszczak M, Aboagye EOet al., 2013, Design of symmetrical and nonsymmetrical N,N-dimethylaminopyridine derivatives as highly potent choline kinase alpha inhibitors, MedChemComm, Vol: 4, Pages: 693-696, ISSN: 2040-2503

Choline kinase alpha is hyperactivated in many solid tumours and regulates malignant progression, making it a promising cancer drug target. The successful design and synthesis of novel inhibitors with high cellular activity are described.

Journal article

Smith G, Carroll L, Aboagye EO, 2012, New Frontiers in the Design and Synthesis of Imaging Probes for PET Oncology: Current Challenges and Future Directions, MOLECULAR IMAGING AND BIOLOGY, Vol: 14, Pages: 653-666, ISSN: 1536-1632

Journal article

Perumal M, Stronach EA, Gabra H, Aboagye EOet al., 2012, Evaluation of 2-Deoxy-2-[F-18]Fluoro-D-glucose- and 3 '-Deoxy-3 '-[F-18]Fluorothymidine-Positron Emission Tomography as Biomarkers of Therapy Response in Platinum-Resistant Ovarian Cancer, MOLECULAR IMAGING AND BIOLOGY, Vol: 14, Pages: 753-761, ISSN: 1536-1632

Journal article

Tomasi G, Shepherd T, Turkheimer F, Visvikis D, Aboagye Eet al., 2012, Comparative assessment of segmentation algorithms for tumor delineation on a test-retest [C-11]choline dataset, MEDICAL PHYSICS, Vol: 39, Pages: 7571-7579, ISSN: 0094-2405

Journal article

Trousil S, Kaliszczak M, Carroll L, Aboagye EOet al., 2012, ICL-CCIC-0019, a Novel and Selective Inhibitor of Choline Kinase Alpha with Significant Antitumor Activity, 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Publisher: ELSEVIER SCI LTD, Pages: 56-56, ISSN: 0959-8049

Conference paper

Kaliszczak M, Trousil S, Aberg O, Perumal M, Nguyen QD, Aboagye EOet al., 2012, HDAC6 Inhibitor C1A Synergizes with BEZ-235 in Colon Cancer Cells in Vitro and Potently Inhibits Tumor Growth in Vivo, 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Publisher: ELSEVIER SCI LTD, Pages: 162-162, ISSN: 0959-8049

Conference paper

Fortt R, Smith G, Awais RO, Luthra SK, Aboagye EOet al., 2012, Automated GMP Synthesis of [F-18]ICMT-11 for In Vivo Imaging of Caspase-3 Activity, NUCLEAR MEDICINE AND BIOLOGY, Vol: 39, Pages: 1000-1005, ISSN: 0969-8051

Journal article

Carroll L, Perumal M, Vasdev N, Robins E, Aboagye EOet al., 2012, Radiosynthesis and in vivo tumor uptake of 2-deoxy-2-[F-18]fluoro-myo-inositol, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, Vol: 22, Pages: 6148-6150, ISSN: 0960-894X

Journal article

Sharma R, Kallur KG, Ryu JS, Parameswaran RV, Lindman H, Avril N, Gleeson FV, Lee JD, Lee KH, O'Doherty MJ, Groves AM, Miller MP, Paterson CL, Coombes C, Aboagye EOet al., 2012, Test-retest reproducibility of [F-18]fluciclatide PET imaging in subjects with solid tumors, 25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Publisher: SPRINGER, Pages: S226-S226, ISSN: 1619-7070

Conference paper

Lake MC, Quang-De N, Ali S, Aboagye EOet al., 2012, Development of a Novel Molecular Sensor for Imaging Estrogen Receptor-Coactivator Protein-Protein Interactions, PLOS ONE, Vol: 7, ISSN: 1932-6203

Journal article

Smith G, Sala R, Carroll L, Behan K, Glaser M, Robins E, Quang-De N, Aboagye EOet al., 2012, Synthesis and evaluation of nucleoside radiotracers for imaging proliferation, NUCLEAR MEDICINE AND BIOLOGY, Vol: 39, Pages: 652-665, ISSN: 0969-8051

Journal article

Aboagye EO, Gilbert FJ, Fleming IN, Beer AJ, Cunningham VJ, Marsden PK, Visvikis D, Gee AD, Groves AM, Kenny LM, Cook GJ, Kinahan PE, Myers M, Clarke Let al., 2012, Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials, EUROPEAN RADIOLOGY, Vol: 22, Pages: 1465-1478, ISSN: 0938-7994

Journal article

Contractor K, Challapalli A, Tomasi G, Rosso L, Wasan H, Stebbing J, Kenny L, Mangar S, Riddle P, Palmieri C, Al-Nahhas A, Sharma R, Turkheimer F, Coombes RC, Aboagye Eet al., 2012, Imaging of cellular proliferation in liver metastasis by [F-18]fluorothymidine positron emission tomography: effect of therapy, PHYSICS IN MEDICINE AND BIOLOGY, Vol: 57, Pages: 3419-3433, ISSN: 0031-9155

Journal article

Tomasi G, Kimberley S, Rosso L, Aboagye E, Turkheimer Fet al., 2012, Double-input compartmental modeling and spectral analysis for the quantification of positron emission tomography data in oncology, PHYSICS IN MEDICINE AND BIOLOGY, Vol: 57, Pages: 1889-1906, ISSN: 0031-9155

Journal article

Tomasi G, Turkheimer F, Aboagye E, 2012, Importance of Quantification for the Analysis of PET Data in Oncology: Review of Current Methods and Trends for the Future, MOLECULAR IMAGING AND BIOLOGY, Vol: 14, Pages: 131-146, ISSN: 1536-1632

Journal article

Contractor K, Aboagye EO, Jacob J, Challapalli A, Coombes RC, Stebbing Jet al., 2012, Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [F-18] 3 '-deoxy-3 '-fluorothymidine PET: a pilot study, BIOMARKERS IN MEDICINE, Vol: 6, Pages: 231-233, ISSN: 1752-0363

Journal article

Quang-De N, Challapalli A, Smith G, Fortt R, Aboagye EOet al., 2012, Imaging apoptosis with positron emission tomography: 'Bench to bedside' development of the caspase-3/7 specific radiotracer [F-18]ICMT-11, EUROPEAN JOURNAL OF CANCER, Vol: 48, Pages: 432-440, ISSN: 0959-8049

Journal article

Aberg O, Pisaneschi F, Smith G, Quang-De N, Stevens E, Aboagye EOet al., 2012, F-18-labelling of a cyclic pentapeptide inhibitor of the chemokine receptor CXCR4, JOURNAL OF FLUORINE CHEMISTRY, Vol: 135, Pages: 200-206, ISSN: 0022-1139

Journal article

Soloviev D, Lewis D, Honess D, Aboagye Eet al., 2012, [(18)F]FLT: an imaging biomarker of tumour proliferation for assessment of tumour response to treatment., Eur J Cancer, Vol: 48, Pages: 416-424

The paradigm of drug development is shifting towards early use of imaging biomarkers as surrogate end-points in clinical trials. Quantitative Imaging in Cancer: Connecting Cellular Processes (QuIC-ConCePT) is an initiative to qualify complementary imaging biomarkers (IB) of proliferation, cell death and tumour heterogeneity as possible tools in early phase clinical trials to help pharmaceutical developers in 'go, no-go' decisions early in the process of drug development. One of the IBs is [(18)F]3'-deoxy-3'-fluorothymidine with Positron Emission Tomography (FLT-PET). We review results of recent clinical trials using FLT-PET for monitoring tumour response to drug treatment and discuss the potential and the possible pitfalls of using this IB as a surrogate end-point in early phase clinical trials for assessing tumour response to drug treatment. From first human trial results it seems that the degree of FLT accumulation in tumours is governed not only by the tumour proliferation rate but also by other factors. Nevertheless FLT-PET could potentially be used as a negative predictor of tumour response to chemotherapy, and hence evaluation of this IB is granted in multi-centre clinical trials.

Journal article

Witney TH, Alam IS, Turton DR, Smith G, Carroll L, Brickute D, Twyman FJ, Quang-De N, Tomasi G, Awais RO, Aboagye EOet al., 2012, Evaluation of Deuterated F-18- and C-11-Labeled Choline Analogs for Cancer Detection by Positron Emission Tomography, CLINICAL CANCER RESEARCH, Vol: 18, Pages: 1063-1072, ISSN: 1078-0432

Journal article

Evans HL, Slade RL, Carroll L, Smith G, Nguyen Q-D, Iddon L, Kamaly N, Stoeckmann H, Leeper FJ, Aboagye EO, Spivey ACet al., 2012, Copper-free click-a promising tool for pre-targeted PET imaging, CHEMICAL COMMUNICATIONS, Vol: 48, Pages: 991-993, ISSN: 1359-7345

Journal article

Vengadabady L, Thielemans K, McCabe D, Challapalli A, Spinks TJ, Aboagye Eet al., 2012, Comparing respiratory and patient movement during dynamic PET, 2012 IEEE NUCLEAR SCIENCE SYMPOSIUM AND MEDICAL IMAGING CONFERENCE RECORD (NSS/MIC), Pages: 4005-4008, ISSN: 1095-7863

Journal article

Contractor KB, Kenny LM, Coombes CR, Turkheimer FE, Aboagye EO, Rosso Let al., 2012, Evaluation of limited blood sampling population input approaches for kinetic quantification of [F-18]fluorothymidine PET data, EJNMMI RESEARCH, Vol: 2, ISSN: 2191-219X

Journal article

Aboagye EO, Smith G, Robins EG, Zhao Yet al., 2012, WO2012/040133: Novel precursor. [Deuterated fluorocholine precursor]

Patent

Aboagye EO, Robins EG, Smith G, Leyton J, Zhao Y, Turton D, Brickute D, Wilson A, Bhalla Ret al., 2012, WO2012/040138: Novel radiotracer. [Deuterated fluorocholine imaging agent]

Patent

Aboagye EO, Robins EG, Smith G, Luthra Set al., 2012, WO2012/040151: Isotopic carbon choline analogues. [Deuterated choline imaging agent]

Patent

Aboagye EO, Kaliszczak M, 2012, WO2012/175973: Combination treatment comprising a HDAC6 inhibitor and and AKT inhibitor

Patent

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: id=00169625&limit=30&person=true&page=6&respub-action=search.html